Outlook Therapeutics Receives Nasdaq Bid-Price Deficiency Notice, Must Regain $1.00 by March 24, 2027
OTLK has more than doubled off its 52-week low of $0.161.
Summary
Nasdaq notified Outlook Therapeutics on September 25, 2026, that its stock has closed below $1.00 for 30 consecutive business days. The company has until March 24, 2027, to regain compliance or face delisting.
Key Events · Legal and Risk Events · OTLK
-
Nasdaq Deficiency Notice Received
On September 25, 2026, Nasdaq notified Outlook Therapeutics that its stock closed below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2).
-
Compliance Deadline Set
The company has 180 calendar days, until March 24, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.
-
Delisting Risk
If compliance is not regained by the deadline, Nasdaq may initiate delisting proceedings. The company may appeal, but success is not assured.
-
Reverse Split Under Consideration
Management states it will evaluate available options, including a reverse stock split, to cure the deficiency. Shareholders previously approved a reverse split authorization in July 2026.
Analysis · OTLK · Life Sciences
Outlook Therapeutics has fallen back below Nasdaq's $1.00 minimum bid price for 30 consecutive business days, triggering a formal deficiency notice. The company now has 180 calendar days, until March 24, 2027, to regain compliance. This comes just two months after the company regained compliance in July 2026 and shortly after a $55 million public offering priced at $0.99 per unit. The stock currently trades at $0.5989, well below the required threshold. Management says it will evaluate options, including a reverse stock split, but there is no guarantee of success. A delisting would severely impair liquidity and access to capital for a company already facing going-concern doubts.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 36.7% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OTLK was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $139.6M. The 52-week trading range was $0.16 to $2.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.